In this review:
14-3-3η: a novel biomarker for RA?
ABT-122 promising for immune-mediated inflammatory disease
Patient vs physician prediction of remission
How much weight to put on the PtGA?
Apremilast before biologics: cost-saving strategy in PsA
Much ANA testing does not reflect high-value care and wastes healthcare resources
Tapering and stopping DMARDs in RA pts in stable remission
TNF inhibitor dose reduction strategy feasible in RA
HZV protocol safe with current biologic therapy
Secukinumab shows promise in active AS and also in active PsA
Download PDF